Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: J Allergy Clin Immunol Pract. 2021 Aug 2;9(11):4095–4102. doi: 10.1016/j.jaip.2021.07.044

Table 3.

Hematologic and Lymphatic Features

PI3KCD n=33 PI3KR1 n=7 Combined n=40
NON-MALIGNANT

Splenomegaly 18 (54.5%) 4 (57.1%) 22 (55.0%)

Lymphadenopathy 16 (48.5%) 5 (71.4%) 21 (52.5%)

Hepatomegaly 9 (27.2%) 2 (28.6%) 11 (27.5%)

Hemolytic Anemia 7 (21.2%) 0 7 (17.5%)

Nodular Lymphoid Hyperplasia 4 (12.1%) 0 4 (10.0%)

Pancytopenia 4 (12.1%) 0 4 (10.0%)

Immune Thrombocytopenia 3 (9.1%) 1 (14.3%) 4 (10.0%)

Factor XI deficiency 2 (6.1%) 0 2 (5.0%)
Factor IX deficiency 1 (3.0%) 0 1 (2.5%)

Spherocytosis 1 (3.0%) 0 1 (2.5%)

TTP 1 (3.0%) 0 1 (2.5%)

MALIGNANT

Lymphoma – All 4 (12.1%) 1 (14.3%) 5 (12.5%)

Non-Hodgkin’s Lymphoma 1 (3.0%) 1 (14.3%) 2 (5.0%)

Hodgkin’s Lymphoma 1 (3.0%) 0 1 (2.5%)

Diffuse large B cell lymphoma 2 (6.1%) 0 2 (5.0%)

MALT lymphoma 2 (6.1%) 0 2 (5.0%)

Other - Hurthle cell carcinoma of thyroid (1)
- Dysgerminoma (1)
- Dysgerminoma (1) 3 (7.5%)

Benign lymphoid hyperplasia was commonly reported. Five patients (12.5%) developed lymphoma. The history of lymphoma was significantly associated with EBV (P=0.004) but was not with other herpesviruses (P=0.056).